Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20747590 | 0.86 | SLC7A5 (0.35) | SLC7A5 | |
| SCHEMBL20747653 | 0.86 | LMNA (0.39) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL20747670 | 0.79 | SLC7A5 (0.42) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL18067492 | 0.79 | SLC7A5 (0.42) | SLC7A5DPP4DPP8DPP9DPP7 | |
| SCHEMBL22601425 | 0.78 | LMNA (0.36) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL20747624 | 0.78 | DPP4 (0.33) | LMNAHSD17B10DPP4DPP8DPP9 | |
| SCHEMBL20747630 | 0.76 | SLC15A1 (0.34) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL21230050 | 0.76 | LMNA (0.38) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL20747689 | 0.75 | LMNA (0.36) | LMNA | |
| SCHEMBL20747747 | 0.74 | SLC7A5 (0.38) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | LMNA 2972/4885HSD17B10 3567/4885TSHR 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.